CD Skripsi
Respon Biokimia Dan Virologis Setelah Terapi Antiviral Pada Penderita Hepatitis B Kronik Di RSUD Arifin Achmad Provinsi Riau
Hepatitis B is an important health problem throughout the world, about 2 billion people are infected with hepatitis B and 240 million of them suffer chronic hepatitis B. Antiviral therapy given to patients with chronic hepatitis B aims to suppress viral replication and inhibits the progression of inflammation and necrosis of the liver. Evaluation of therapy is needed to analyze the possibility of antiviral resistance which can increase the risk of complications. Therapy evaluation is observed by monitoring at biochemical and virological responses after at least 1 year of antiviral therapy. The purpose of this study was to determine the biochemical response and virological response in chronic hepatitis B patients in RSUD Arifin Achmad Provinsi Riau period January 2013 – Desember 2017 who received antiviral therapy. This was a descriptive study with a cross-sectional approach using medical record data of chronic hepatitis B patients. This research included 20 cases of chronic hepatitis B. The results showed that chronic hepatitis B patients who received antiviral therapy aged 45.60 ± 11,64 years and most were male (75%). The most widely of antiviral therapy is telbivudin (80%). After at least 1 year of antiviral therapy, most patients still demonstrated increased ALT levels of 1-2x ULN (45%) and undetectable HBV DNA levels (45%).
Keywords : antiviral, biochemichal response, hepatitis B, virological response
Tidak tersedia versi lain